Use of the pat nanopeptide in the treatment of autoimmune diseases
US9427455B2 · kind B2 · utility
0Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2009 |
| Grant date | Aug 30, 2016 |
| Priority date | — |
| Expiry date | Dec 25, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.